Automated Liquid Handling Systems Market: Industry Trends and Global Forecasts - Distribution by Pipetting Technology, Washing Technology, Modality Type of Instrument, Application, End User and Key Geographical Regions

The global automated liquid handling systems market is estimated to grow from USD 3.50 billion in the current year to USD 6.35 billion by 2035, at a CAGR of 6.8% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Pipetting Technology

Contact Technology
Air Displacement Technology
Piston / Positive Displacement Technology
Acoustic Technology
Free-jet Technology

Washing Technology

Ultrasonic Technology
Acoustic Technology
Centrifugal Technology

Modality

Fixed Tips
Disposable Tips

Type of Instrument

Standalone
Individual Benchtop Workstation
Multi Instrument Systems
Others

Application

Serial Dilution
Plate Replication
PCR / qPCR Setup
Plate Reformatting
High-throughput Screening
Whole Genome Amplification
Cell Culture
ELISA
Cell-based Assays
Bead Washing
Other Applications

End User

Biotechnology and Pharmaceutical Companies
Academics and Government Research Institutes
Hospitals and Diagnostic Centers
Other End Users

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET: GROWTH AND TRENDS

In recent years, the biopharmaceutical domain has witnessed several advancements in the field of laboratory sciences, including the emergence of automated systems. The use of automated liquid handling systems in the pharmaceutical industry has revolutionized the way modern laboratories operate. The growth of this market is primarily driven by the advantages offered by automated liquid handling systems over manual methods. Owing to enhanced throughput, higher precision and better workflows that allow significant time saving, an increasing number of laboratories have started adopting these systems. Further, in response to limitations of conventional systems, and the need for automating liquid handling processes, a number of players have developed automated liquid handling systems with advanced features to cater to the needs of various end users. This has provided laboratories with a competitive edge in the past two decades. Considering their advantages and diverse applications across biological research, molecular biology assays, epigenetics and genomics, automated liquid handling systems have been recognized as one of the most effective liquid handling systems.

Driven by rapid advancements in liquid handling technologies and increasing adoption of such systems, the market for automated liquid handling systems is expected to witness a steady growth in the foreseen future

GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET: KEY INSIGHTS

The report delves into the current state of global automated liquid handling systems market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, 70 well-established players across the globe claim to offer more than 150 automated pipetting systems; more than 70% of these systems can be used as integrated workstations.

Automated pipetting systems are equipped with advanced features to enhance reproducibility and workflow accuracy; nearly 60% of the systems offer barcode identification for tracking sample reagents conveniently.
In pursuit of building a competitive edge in this industry, stakeholders are actively upgrading their existing automated pipetting systems in order to augment their product portfolio offerings.
During our research, we identified more than 100 automated microplate washers that have various applications in the biopharmaceutical and pharmaceutical industries.
Close to 80% of the automated microplate washers are used as stand-alone workstations, offering flexibility in sample preparation; over 95% of such systems are compatible with flat microplates.
It is worth highlighting that players are focused on the integration of advanced features into their automated microplate washers to comply with the evolving industry benchmarks.
The partnership activity in this domain has increased at a CAGR of over 30%; in fact, the maximum deals related to automated liquid handling systems have been inked in the last three years.
Around 500 patents related to automated liquid handling systems have recently been filed / granted by various stakeholders, indicating the growing pace of innovation in this field.
With the rising demand for automated pipetting systems, the market is expected to grow at an annualized rate of more than 6.9% till 2035.
The current and projected future automated pipetting systems market opportunity is likely to be well distributed across various applications, end users and key geographical regions.

Growth in the automated microplate washer’s domain is anticipated to be primarily driven by the rising demand of acoustic technology; North America is expected to capture larger share (35%) of the market by 2035.

GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET: KEY SEGMENTS

Air Displacement Technology Segment Occupies the Largest Share of the Automated Liquid Handling Systems Market

Based on pipetting technology, the market is segmented into contact technology, air displacement technology, piston / positive displacement technology, acoustic technology and free-jet technology. At present, air displacement technology segment holds the majority share (~30%) of the global automated liquid handling systems market. Additionally, the acoustic technology segment is likely to grow at a faster pace compared to the other segments.

By Modality, Disposable Tips is the Fastest Growing Segment of the Global Automated Liquid Handling Systems Market

Based on the modality, the market is segmented into fixed tips and disposable tips. Currently, the disposable tips segment captures the highest proportion (~75%) of the global automated liquid handling systems market. It is worth highlighting that the automated liquid handling systems market for disposable tips segment is likely to grow at a relatively higher CAGR.

Standalone Segment Occupies the Largest Share of the Automated Liquid Handling Systems Market by Type of Instrument

Based on the type of instrument, the market is segmented into standalone, individual benchtop workstation, multi-instrument systems and others. At present, the standalone segment holds the maximum share (~35%) of the automated liquid handling systems market. In addition, the multi-instrument systems segment is likely to grow at a relatively higher CAGR.

By Application, the High-throughput Screening Segment is the Fastest Growing Segment of the Automated Liquid Handling Systems Market During the Forecast Period

Based on the application, the market is segmented into serial dilution, plate replication, PCR / qPCR setup, plate reformatting, high-throughput screening, whole genome amplification, cell culture, ELISA, cell-based assays, bead washing and other applications. Currently, serial dilution segment captures the highest proportion (>30%) of the automated liquid handling systems market. Further, it is worth highlighting that the automated liquid handling systems market for high-throughput screening is likely to grow at a relatively higher CAGR.

Biotechnology and Pharmaceutical Companies Segment Account for the Largest Share of the Global Automated Liquid Handling Systems Market

Based on the end user, the market is segmented into biotechnology and pharmaceutical companies, academic and government research institutes, hospitals and diagnostic centers and other end users. Currently, biotechnology and pharmaceutical companies segment holds the maximum share (~45%) of the global automated liquid handling systems market. This trend is likely to remain the same in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. Currently, North America (~45%) dominates the automated liquid handling systems market and accounts for the largest revenue share. However, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Automated Liquid Handling Systems Market

Agilent Technologies
Beckman Coulter Life Sciences
Eppendorf
Hamilton Robotics
MyGenostics
Tecan
Thermo Fisher Scientific

GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global automated liquid handling systems market, focusing on key market segments, including [A] pipetting technology, [B] washing technology, [C] modality, [D] type of instrument, [E] application, [F] end user and [G] key geographical regions.
Automated Pipetting Systems Market Landscape: A comprehensive evaluation of automated pipetting systems, considering various parameters, such as [A] pipetting technology, [B] certification(s), [C] type of instrument(s) by assembly, [D] pipetting head option(s), [E] weight of automated pipetting system (in kg), [F] compatible labware, [G] application area(s), [H] application(s), [I] additional feature(s) and [J] end user(s). Additionally, a comprehensive evaluation of automated pipetting system providers, based on parameters, such as [A] year of establishment, [B] company size (in terms of employee count) and [C] location of headquarters.
Automated Pipetting System Providers Competitiveness Analysis: A comprehensive competitive analysis of automated pipetting system providers, examining factors, such as [A] company strength, [B] product diversity and [C] product strength.
Automated Pipetting System Providers Company Profiles: In-depth profiles of companies engaged in the manufacturing of automated pipetting systems, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio and [D] recent developments and an informed future outlook.
Automated Microplate Washers Market Landscape: A comprehensive evaluation of automated microplate washers, considering various parameters, such as [A] type of instrument(s), [B] compatible microplate(s), [C] weight of automated microplate washers (in Kg), [D] compatible labware, [E] application(s), and [F] end user(s). Additionally, a comprehensive evaluation of automated microplate washer providers, based on parameters, such as [A] year of establishment, [B] company size (in terms of employee count) and [C] location of headquarters.
Automated Microplate Washer Providers Competitiveness Analysis: A comprehensive competitive analysis of automated microplate washer providers, examining factors, such as [A] company strength, [B] product diversity and [C] product strength.
Automated Microplate Washer Providers Company Profiles: In-depth profiles of companies engaged in the manufacturing of automated microplate washers, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio and [D] recent developments and an informed future outlook.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the automated liquid handling systems market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of automated liquid handling system, [D] most popular products, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the automated liquid handling systems domain, based on various relevant parameters, such as [A] patent publication year, [B] type of patent, [C] patent jurisdiction, [D] CPC symbols, [F] type of applicant, [G] emerging focus areas, [H] leading players, [I] benchmarking analysis and [J] patent valuation.
SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of automated liquid handling systems market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs Covering All Analytical Modules
Up to 15% Complimentary Content Customization
In-Depth Report Walkthrough with the Research Team
Complimentary Report Update if the Report is 6+ Months Old

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.5. COVID Impact / Related Factors
1.2.5.6. Market Access
1.2.5.7. Healthcare Policies
1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of Automated Liquid Handling Systems
3.3. Manual versus Automated Liquid Handling
3.4. Automated Pipetting Systems
3.4.1. Working Mechanism of Automated Pipetting Systems
3.4.2. Types of Automated Pipetting Systems
3.4.2.1. Tip-based Pipetting Systems
3.4.2.2. Non-tip based Pipetting Systems
3.4.3. Advantages of Automated Pipetting Systems
3.5. Automated Microplate Washers
3.5.1. Features of an Ideal Automated Microplate Washer
3.6. Applications of Automated Liquid Handling Systems
3.7. Challenges in Adoption of Automated Liquid Handling Systems
3.8. Future Perspectives

4. AUTOMATED PIPETTING SYSTEMS: MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Automated Pipetting Systems: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by Pipetting Technology
4.2.3. Analysis by Certification(s)
4.2.4. Analysis by Type of Instrument(s) by Assembly
4.2.5. Analysis by Pipetting Head Option(s)
4.2.6. Analysis by Weight of Automated Pipetting System (in Kg)
4.2.7. Analysis by Compatible Labware
4.2.8. Analysis by Application Area(s)
4.2.9. Analysis by Application(s)
4.2.10. Analysis by Additional Feature(s)
4.2.11. Analysis by End User(s)
4.3. Automated Pipetting System Providers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Company Size and Location of Headquarters (Region-wise)
4.3.5. Analysis by Location of Headquarters (Country-wise)
4.3.6. Most Active Players: Analysis by Number of Automated Pipetting Systems Manufactured

5. AUTOMATED PIPETTING SYSTEM PROVIDERS: COMPETITIVENESS ANALYSIS

5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Automated Pipetting System Providers
5.4.1. Companies based in North America (Peer Group I)
5.4.2. Companies based in Europe (Peer Group II)
5.4.3. Companies based in Asia-Pacific and Rest of the World (Peer Group III)

6. AUTOMATED PIPETTING SYSTEM PROVIDERS: COMPANY PROFILES

6.1. Chapter Overview
6.2. Beckman Coulter Life Sciences
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Product Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Eppendorf
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Product Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. Hamilton Robotics
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. MyGenostics
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook

7. AUTOMATED MICROPLATE WASHERS: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Automated Microplate Washers: Overall Market Landscape
7.2.1. Analysis by Type of Instrument(s) by Assembly
7.2.2. Analysis by Compatible Microplate(s)
7.2.3. Analysis by Weight of Automated Microplate Washer (in Kg)
7.2.4. Analysis by Compatible Software
7.2.5. Analysis by Compatible Labware
7.2.6. Analysis by Application Area(s)
7.2.7. Analysis by Application(s)
7.2.8. Analysis by End User(s)
7.3. Automated Microplate Washer Providers Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region-wise)
7.3.4. Analysis by Company Size and Location of Headquarters (Region-wise)
7.3.5. Analysis by Location of Headquarters (Country-wise)
7.3.6. Most Active Players: Analysis by Number of Automated Microplate Washers Manufactured

8. AUTOMATED MICROPLATE WASHER PROVIDERS: COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Company Competitiveness Analysis: Automated Microplate Washer Providers
8.4.1. Companies based in North America (Peer Group I)
8.4.2. Companies based in Europe (Peer Group II)
8.4.3. Companies based in Asia-Pacific and Rest of the World (Peer Group III)

9. AUTOMATED MICROPLATE WASHER PROVIDERS: COMPANY PROFILES

9.1. Chapter Overview
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Product Portfolio
9.2.4. Recent Developments and Future Outlook
9.3. Tecan
9.3.1. Company Overview
9.3.2. Financial Information
9.3.3. Product Portfolio
9.3.4. Recent Developments and Future Outlook
9.4. Thermo Fisher Scientific
9.4.1. Company Overview
9.4.2. Financial Information
9.4.3. Product Portfolio
9.4.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Automated Liquid Handling Systems: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Automated Liquid Handling System(s)
10.3.5. Analysis by Product and Type of Partnership
10.3.6. Most Popular Products: Distribution by Number of Partnerships
10.3.7. Most Active Players: Analysis by Type of Partnership
10.3.8. Analysis by Geography
10.3.8.1. Local and International Agreements
10.3.8.2. Intracontinental and Intercontinental Agreements

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Automated Liquid Handling Systems: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Annual Number of Granted Patents and Patent Applications
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Sections
11.3.5. Word Cloud Analysis: Emerging Focus Areas
11.3.6. Analysis by Type of Organization
11.3.7. Leading Industry Players: Analysis by Number of Patents
11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
11.3.9. Leading Individual Assignees: Analysis by Number of Patents
11.4. Automated Liquid Handling Systems: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Automated Liquid Handling Systems: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview
12.2. Methodology and Key Assumptions
12.3. Global Automated Liquid Handling Systems Market, Till 2035
12.3.1. Automated Liquid Handling Systems Market: Distribution by Type of Automated Liquid Handling System
12.3.1.1. Automated Pipetting Systems Market: Till 2035
12.3.1.1.1. Automated Pipetting Systems Market: Distribution by Pipetting Technology
12.3.1.1.1.1. Automated Pipetting Systems Market for Contact Technology, Till 2035
12.3.1.1.1.2. Automated Pipetting Systems Market for Air Displacement Technology, Till 2035
12.3.1.1.1.3. Automated Pipetting Systems Market for Piston / Positive Displacement Technology, Till 2035
12.3.1.1.1.4. Automated Pipetting Systems Market for Acoustic Technology, Till 2035
12.3.1.1.1.5. Automated Pipetting Systems Market for Free-jet Technology, Till 2035
12.3.1.1.2. Automated Pipetting Systems Market: Distribution by Modality
12.3.1.1.2.1. Automated Pipetting Systems Market for Fixed Tips, Till 2035
12.3.1.1.2.2. Automated Pipetting Systems Market for Disposable Tips, Till 2035
12.3.1.1.3. Automated Pipetting Systems Market: Distribution by Type of Instrument
12.3.1.1.3.1. Automated Pipetting Systems Market for Standalone, Till 2035
12.3.1.1.3.2. Automated Pipetting Systems Market for Individual Benchtop Workstation, Till 2035
12.3.1.1.3.1. Automated Pipetting Systems Market for Multi Instrument System, Till 2035
12.3.1.1.3.2. Automated Pipetting Systems Market for Others, Till 2035
12.3.1.1.4. Automated Pipetting Systems Market: Distribution by Application
12.3.1.1.4.1. Automated Pipetting Systems Market for Serial Dilution, Till 2035
12.3.1.1.4.2. Automated Pipetting Systems Market for Plate Replication, Till 2035
12.3.1.1.4.3. Automated Pipetting Systems Market for PCR / qPCR Setup, Till 2035
12.3.1.1.4.4. Automated Pipetting Systems Market for Plate Reformatting, Till 2035
12.3.1.1.4.5. Automated Pipetting Systems Market for High-throughput Screening, Till 2035
12.3.1.1.4.6. Automated Pipetting Systems Market for Whole Genome Amplification, Till 2035
12.3.1.1.4.7. Automated Pipetting Systems Market for Cell Culture, Till 2035
12.3.1.1.4.8. Automated Pipetting Systems Market for Other Applications, Till 2035
12.3.1.1.5. Automated Pipetting Systems Market: Distribution by End User
12.3.1.1.5.1. Automated Pipetting Systems Market for Biotechnology and Pharmaceutical Companies, Till 2035
12.3.1.1.5.2. Automated Pipetting Systems Market for Academic and Government Research Institutes, Till 2035
12.3.1.1.5.3. Automated Pipetting Systems Market for Hospitals and Diagnostic Centers, Till 2035
12.3.1.1.5.4. Automated Pipetting Systems Market for Other End Users, Till 2035
12.3.1.1.6. Automated Pipetting Systems Market: Distribution by Key Geographical Regions
12.3.1.1.6.1 Automated Pipetting Systems Market in North America, Till 2035
12.3.1.1.6.2. Automated Pipetting Systems Market in Europe, Till 2035
12.3.1.1.6.3. Automated Pipetting Systems Market in Asia-Pacific, Till 2035
12.3.1.1.6.4. Automated Pipetting Systems Market in Middle East and North Africa, Till 2035
12.3.1.1.6.5. Automated Pipetting Systems Market in Latin America, Till 2035
12.3.1.2. Automated Microplate Washers Market: Till 2035
12.3.1.2.1. Automated Microplate Washers Market: Distribution by Washing Technology
12.3.1.2.1.1. Automated Microplate Washers Market for Ultrasonic Technology, Till 2035
12.3.1.2.1.2. Automated Microplate Washers Market for Acoustic Technology, Till 2035
12.3.1.2.1.3. Automated Microplate Washers Market for Centrifugal Technology, Till 2035
12.3.1.2.2. Automated Microplate Washers Market: Distribution by Application
12.3.1.2.2.1. Automated Microplate Washers Market for ELISA, Till 2035
12.3.1.2.2.2. Automated Microplate Washers Market for Cell-based Assays, Till 2035
12.3.1.2.2.3. Automated Microplate Washers Market for Bead Washing, Till 2035
12.3.1.2.2.4. Automated Microplate Washers Market for Other Applications, Till 2035
12.3.1.2.3. Automated Microplate Washers Market: Distribution by End User
12.3.1.2.3.1. Automated Microplate Washers Market for Biotechnology and Pharmaceutical Companies, Till 2035
12.3.1.2.3.2. Automated Microplate Washers Market for Academic and Government Research Institutes, Till 2035
12.3.1.2.3.3. Automated Microplate Washers Market for Hospitals and Diagnostic Centers, Till 2035
12.3.1.2.3.4. Automated Microplate Washers Market for Other End Users, Till 2035
12.3.1.2.4. Automated Microplate Washers Market: Distribution by Key Geographical Regions
12.3.1.2.4.1. Automated Microplate Washers Market in North America, Till 2035
12.3.1.2.4.2. Automated Microplate Washers Market in Europe, Till 2035
12.3.1.2.4.3. Automated Microplate Washers Market in Asia-Pacific, Till 2035
12.3.1.2.4.4. Automated Microplate Washers Market in Middle East and North Africa, Till 2035
12.3.1.2.4.5. Automated Microplate Washers Market in Latin America, Till 2035

13. SWOT ANALYSIS

13.1. Chapter Overview
13.2. Automated Liquid Handling Systems: SWOT Analysis
13.3. Comparison of SWOT Factors
13.3.1. Weaknesses
13.3.2. Opportunities
13.3.3. Threats
13.4. Concluding Remarks

14. CONCLUDING REMARKS15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

36.1.2. Vector Manufacturing Market in Asia-Pacific for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.1.3. Vector Manufacturing Market in Asia-Pacific for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2. Vector Manufacturing Market in Asia-Pacific: Distribution by Type of Vector Manufactured
36.2.1. Vector Manufacturing Market in Asia-Pacific for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2.2. Vector Manufacturing Market in Asia-Pacific for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2.3. Vector Manufacturing Market in Asia-Pacific for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2.4. Vector Manufacturing Market in Asia-Pacific for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2.5. Vector Manufacturing Market in Asia-Pacific for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.2.6. Vector Manufacturing Market in Asia-Pacific for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.3. Vector Manufacturing Market in Asia-Pacific: Distribution by Application Area
36.3.1. Vector Manufacturing Market in Asia-Pacific for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.3.2. Vector Manufacturing Market in Asia-Pacific for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.3.3. Vector Manufacturing Market in Asia-Pacific for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4. Vector Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
36.4.1. Vector Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.2. Vector Manufacturing Market in Asia-Pacific for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.3. Vector Manufacturing Market in Asia-Pacific for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.4. Vector Manufacturing Market in Asia-Pacific for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.5. Vector Manufacturing Market in Asia-Pacific for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.6. Vector Manufacturing Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.7. Vector Manufacturing Market in Asia-Pacific for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.8. Vector Manufacturing Market in Asia-Pacific for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.9. Vector Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.10. Vector Manufacturing Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.4.11. Vector Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.5. Vector Manufacturing Market in Asia-Pacific: Distribution by Type of Manufacturer
36.5.1. Vector Manufacturing Market in Asia-Pacific for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
36.5.2. Vector Manufacturing Market in Asia-Pacific for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

37. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

37.1. Vector Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
37.1.1. Vector Manufacturing Market in Middle East and North Africa for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.1.2. Vector Manufacturing Market in Middle East and North Africa for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.1.3. Vector Manufacturing Market in Middle East and North Africa for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2. Vector Manufacturing Market in Middle East and North Africa: Distribution by Type of Vector Manufactured
37.2.1. Vector Manufacturing Market in Middle East and North Africa for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2.2. Vector Manufacturing Market in Middle East and North Africa for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2.3. Vector Manufacturing Market in Middle East and North Africa for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2.4. Vector Manufacturing Market in Middle East and North Africa for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2.5. Vector Manufacturing Market in Middle East and North Africa for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.2.6. Vector Manufacturing Market in Middle East and North Africa for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.3. Vector Manufacturing Market in Middle East and North Africa: Distribution by Application Area
37.3.1. Vector Manufacturing Market in Middle East and North Africa for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.3.2. Vector Manufacturing Market in Middle East and North Africa for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.3.3. Vector Manufacturing Market in Middle East and North Africa for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4. Vector Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
37.4.1. Vector Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.2. Vector Manufacturing Market in Middle East and North Africa for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.3. Vector Manufacturing Market in Middle East and North Africa for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.4. Vector Manufacturing Market in Middle East and North Africa for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.5. Vector Manufacturing Market in Middle East and North Africa for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.6. Vector Manufacturing Market in Middle East and North Africa for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.7. Vector Manufacturing Market in Middle East and North Africa for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.8. Vector Manufacturing Market in Middle East and North Africa for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.9. Vector Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.10. Vector Manufacturing Market in Middle East and North Africa for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.4.11. Vector Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.5. Vector Manufacturing Market in Middle East and North Africa: Distribution by Type of Manufacturer
37.5.1. Vector Manufacturing Market in Middle East and North Africa for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
37.5.2. Vector Manufacturing Market in Middle East and North Africa for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

38. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

38.1. Vector Manufacturing Market in Latin America: Distribution by Scale of Operation
38.1.1. Vector Manufacturing Market in Latin America for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.1.2. Vector Manufacturing Market in Latin America for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.1.3. Vector Manufacturing Market in Latin America for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2. Vector Manufacturing Market in Latin America: Distribution by Type of Vector Manufactured
38.2.1. Vector Manufacturing Market in Latin America for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2.2. Vector Manufacturing Market in Latin America for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2.3. Vector Manufacturing Market in Latin America for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2.4. Vector Manufacturing Market in Latin America for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2.5. Vector Manufacturing Market in Latin America for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.2.6. Vector Manufacturing Market in Latin America for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.3. Vector Manufacturing Market in Latin America: Distribution by Application Area
38.3.1. Vector Manufacturing Market in Latin America for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.3.2. Vector Manufacturing Market in Latin America for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.3.3. Vector Manufacturing Market in Latin America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4. Vector Manufacturing Market in Latin America: Distribution by Therapeutic Area
38.4.1. Vector Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.2. Vector Manufacturing Market in Latin America for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.3. Vector Manufacturing Market in Latin America for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.4. Vector Manufacturing Market in Latin America for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.5. Vector Manufacturing Market in Latin America for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.6. Vector Manufacturing Market in Latin America for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.7. Vector Manufacturing Market in Latin America for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.8. Vector Manufacturing Market in Latin America for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.9. Vector Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.10. Vector Manufacturing Market in Latin America for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.4.11. Vector Manufacturing Market in Latin America for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.5. Vector Manufacturing Market in Latin America: Distribution by Type of Manufacturer
38.5.1. Vector Manufacturing Market in Latin America for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
38.5.2. Vector Manufacturing Market in Latin America for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

39. SURVEY ANALYSIS

39.1. Chapter Overview
39.2. Analysis by Seniority Level of Respondents
39.3. Analysis by Type of Manufacturer
39.4. Analysis by Scale of Operation
39.5. Analysis by Type of Vector Manufactured

40. CONCLUDING REMARKS

41. EXECUTIVE INSIGHTS

41.1. Chapter Overview
41.2. Company A
41.2.1. Company Snapshot
41.2.2. Interview Transcript: Chief Executive Officer
41.3. Company B
41.3.1. Company Snapshot
41.3.2. Interview Transcript: Chief Operating Officer
41.4. Company C
41.4.1. Company Snapshot
41.4.2. Interview Transcript: Djamel Deken, Business Developer
41.5. Company D
41.5.1. Company Snapshot
41.5.2. Interview Transcript: Chief Executive Officer and Chief Scientific Officer
41.6. Company E
41.6.1. Company Snapshot
41.6.2. Interview Transcript: Co-Founder / President, Laurent Ciavatti, Former Business Development Manager and Xavier Leclerc, Head of Gene Therapy
41.7. Company F
41.7.1. Organization Snapshot
41.7.2. Interview Transcript: Director
41.8. Company G
41.8.1. Company Snapshot
41.8.2. Interview Transcript: Former Managing Director
41.9. Company H
41.9.1. Company Snapshot
41.9.2. Interview Transcript: Director of Marketing and Technical Support
41.10. Company I
41.10.1. Organization Snapshot
41.10.2. Interview Transcript: Former Scientific Director
41.11. Company J
41.11.1. Company Snapshot
41.11.2. Interview Transcript: Scientific Director
41.12. Company K
41.12.1. Company Snapshot
41.12.2. Interview Transcript: Former Executive and Scientific Director
41.13. Company L
41.13.1. Organization Snapshot
41.13.2. Interview Transcript: Former Director
41.14. Company M
41.14.1. Company Snapshot
41.14.2. Interview Transcript: Head of Communications
41.15. Company N
41.15.1. Company Snapshot
41.15.2. Interview Transcript: Chief Scientific Officer
41.16. Company O
41.16.1. Company Snapshot
41.16.2. Interview Transcript: Key Account Management
41.17. Company P
41.17.1. Company Snapshot
41.17.2. Interview Transcript: Head of Project Management and Former Marketing Manager
41.18. Company Q
41.18.1. Company Snapshot
41.18.2. Interview Transcript: Director of Business Development
41.19. Company R
41.19.1. Company Snapshot
41.19.2. Interview Transcript: ATMP Key Account Manager
41.20. Independent Consultant
41.20.1. Interview Transcript: Consultant

42. APPENDIX I: TABULATED DATA43. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 7.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 7.2 Vector Manufacturing Operations: Types of Manufacturers
Figure 7.3 Viral Vectors: Manufacturing Process
Figure 7.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 7.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 7.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Figure 7.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Figure 7.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 7.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Figure 7.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Figure 7.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 7.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 7.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Figure 7.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Figure 7.12 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Viral Vector Manufactured
Figure 7.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 8.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 8.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 8.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Figure 8.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Figure 8.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 8.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 8.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Region)
Figure 8.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Country)
Figure 8.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 8.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 8.11 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 9.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Year of Establishment
Figure 9.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Region)
Figure 9.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Country)
Figure 9.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer
Figure 9.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Figure 9.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 9.7 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Figure 9.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 10.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 10.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 10.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Figure 10.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector
Figure 10.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 10.6 Most Active Players: Distribution by Number of Technologies
Figure 11.1 Company Competitiveness Analysis: Viral Vector Manufacturers
based in North America
Figure 11.2 Company Competitiveness Analysis: Viral Vector Manufacturers based
In Europe
Figure 11.3 Company Competitiveness Analysis: Viral Vector Manufacturers based
In Asia-Pacific
Figure 11.4 Company Competitiveness Analysis: Plasmid DNA Manufactures based in North America
Figure 11.5 Company Competitiveness Analysis: Plasmid DNA Manufactures based in Europe
Figure 11.6 Company Competitiveness Analysis: Plasmid DNA Manufactures based in Asia-Pacific
Figure 12.1 Catalent Biologics: Annual Revenues
Figure 12.2 Charles River Laboratories: Annual Revenues
Figure 12.3 Thermo Fisher Scientific: Annual Revenues
Figure 13.1 Lonza: Annual Revenues
Figure 14.1 Wuxi AppTec: Annual Revenues
Figure 15.1 Porter’s Five Forces
Figure 15.2 Porter’s Five Forces: Harvey Ball Analysis
Figure 16.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Till 2025
Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 16.4 Partnerships and Collaborations: Distribution by Type of Vector Manufactured
Figure 16.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 16.6 Partnerships and Collaborations: Distribution by Application Area
Figure 16.7 Most Active Players: Distribution by Number of Partnerships
Figure 16.8 Partnerships and Collaborations: Local and International Agreements
Figure 16.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, Till 2025
Figure 17.2 Recent Expansions: Distribution by Type of Expansion
Figure 17.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 17.4 Most Active Players: Distribution by Number of Expansions
Figure 17.5 Most Active Players: Distribution by Amount Invested
Figure 17.6Recent Expansions: Distribution by Type of Manufacturing Facility
Figure 17.7 Recent Expansions: Distribution by Scale of Operation
Figure 17.8 Recent Expansions: Distribution by Type of Vector Manufactured
Figure 17.9 Recent Expansions: Distribution by Application Area
Figure 17.10 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 17.11 Recent Expansions: Distribution by Location of Expansion
Figure 20.1 Vector and Gene Therapy Manufacturers: Distribution by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Figure 20.2 Vector and Gene Therapy Manufacturers: Distribution by Type of
Vector Manufactured and Company Size
Figure 20.3 Vector and Gene Therapy Contract Manufacturing Organizations: Distribution by Geography
Figure 20.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Geography
Figure 20.5 Vector and Gene Therapy In-House and Contract Manufacturing Organizations: Distribution by Geography
Figure 20.6 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 20.7 Adenoviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 20.8 Lentiviral Vector Manufacturers: Distribution by Location of
Headquarters and Scale of Operation
Figure 20.9 Retroviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 20.10 Plasmid DNA Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Figure 21.1 Viral Vector and Plasmid DNA based Therapies Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 22.1 Outsourcing: Go / No-Go Framework
Figure 22.2 Outsourcing: Go / No-Go Framework Methodology
Figure 22.3 Outsourcing: Go / No-Go Framework for Cell and Gene Therapy Developers
Figure 22.4 Outsourcing: Go / No-Go Framework for Small Companies
Figure 22.5 Outsourcing: Go / No-Go Framework for Mid-sized Companies
Figure 22.6 Outsourcing: Go / No-Go Framework for Large Companies
Figure 23.1 Global Installed Viral Vectors Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Figure 23.2 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Figure 23.3 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Type of Vector Manufactured
Figure 23.4 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 23.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 23.6 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Figure 23.7 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Figure 23.8 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Figure 23.9 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 23.10Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 23.11Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Figure 23.12Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Figure 23.13Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Figure 24.1 Global Demand for Viral Vector and Plasmid DNA (Thousand Patients), Till 2035
Figure 24.2 Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients), Till 2035
Figure 24.3 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Figure 24.4 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Figure 24.5 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Figure 24.6 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Figure 24.7 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients), Till 2035
Figure 24.8 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Figure 24.9 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Figure 24.10Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Figure 24.11Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Figure 24.12Global Vector Manufacturing: Demand and Supply Analysis, Till 2035
Figure 25.1 Market Drivers
Figure 25.2 Market Restraints
Figure 25.3 Market Opportunities
Figure 25.4 Market Challenges
Figure 26.1 Global Vector Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.2 Global Vector Manufacturing Market, Forecasted Estimates (Till 2035), Conservative Scenario (USD Million)
Figure 26.3 Global Vector Manufacturing Market, Forecasted Estimates (Till 2035), Optimistic Scenario (USD Million)
Figure 27.1 Vector Manufacturing Market: Distribution by Scale of Operation
Figure 27.2 Vector Manufacturing Market for Preclinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.3 Vector Manufacturing Market for Clinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.4 Vector Manufacturing Market for Commercial Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.1 Vector Manufacturing Market: Distribution by Type of Vector
Figure 28.2 Vector Manufacturing Market for AAV Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.3 Vector Manufacturing Market for Adenoviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.4 Vector Manufacturing Market for Lentiviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.5 Vector Manufacturing Market for Retroviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.6 Vector Manufacturing Market for Non Viral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.6 Vector Manufacturing Market for Other Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.1 Vector Manufacturing Market: Distribution by Application Area
Figure 29.2 Vector Manufacturing Market for Cell Therapy Manufacturing: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.3 Vector Manufacturing Market for Gene Therapy Manufacturing: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.4 Vector Manufacturing Market for Vaccines: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.1 Vector Manufacturing Market: Distribution by Type of Therapeutic Area
Figure 30.2 Vector Manufacturing Market for Oncological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.3 Vector Manufacturing Market for Rare Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.4 Vector Manufacturing Market for Immunological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.5 Vector Manufacturing Market for Neurological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.6 Vector Manufacturing Market for Sensory Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.7 Vector Manufacturing Market for Metabolic Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.8 Vector Manufacturing Market for Blood Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.9 Vector Manufacturing Market for Musculoskeletal Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.10 Vector Manufacturing Market for Infectious Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.11 Vector Manufacturing Market for Ophthalmic Disorders: Historical
Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.12 Vector Manufacturing Market for Autoimmune Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.13 Vector Manufacturing Market for Other Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 31.1 Vector Manufacturing Market: Distribution by Type of Manufacturer
Figure 31.2 Vector Manufacturing Market for In-house Manufacturers: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 31.3 Vector Manufacturing Market for Contract Manufacturing Organizations: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.1 Vector Manufacturing Market: Distribution by Geography
Figure 32.2 Vector Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.3 Vector Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.4 Vector Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.5 Vector Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 32.5 Vector Manufacturing Market in Latin America and Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 38.1 Survey Analysis: Distribution by Type of Organization
Figure 38.2 Survey Analysis: Distribution by Location of Headquarters
Figure 38.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 38.4 Survey Analysis: Distribution by Type of Manufacturer
Figure 38.5 Survey Analysis: Distribution by Scale of Operation
Figure 38.6 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 39.1 Conclusion: Market Landscape
Figure 39.2 Conclusion: Market Trends
Figure 39.3 Conclusion: Market Forecast and Opportunity Analysis

LIST OF TABLES

Table 6.1 Key Features of Viral Vectors
Table 6.2 Key Features of Small-scale Cell Culture Systems
Table 7.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 7.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Vector Manufacturing Facility, Type of Manufacturer and Scale of Operation
Table 7.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Vector Manufactured
Table 7.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 7.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 8.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 8.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facility, Type of Manufacturer and Scale of Operation
Table 8.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 8.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 9.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 9.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Operation
Table 9.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 9.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 10.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 12.1 Viral Vectors and Plasmid DNA Production in North America: List of Profiled Companies
Table 12.2 Advanced BioScience Laboratories: Company Snapshot
Table 12.3 Advanced BioScience Laboratories: Vector Manufacturing Related Capabilities
Table 12.4 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 12.5 Catalent Biologics: Company Snapshot
Table 12.6 Catalent Biologics: Vector Manufacturing Related Capabilities
Table 12.7 Catalent Biologics: Recent Developments and Future Outlook
Table 12.8 Charles River Laboratories: Company Snapshot
Table 12.9 Charles River Laboratories: Vector Manufacturing Related Capabilities
Table 12.10 Charles River Laboratories: Recent Developments and Future Outlook
Table 12.11 Thermo Fisher Scientific: Company Snapshot
Table 12.12 Thermo Fisher Scientific: Vector Manufacturing Related Capabilities
Table 12.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 12.14 VectorBuilder: Company Snapshot
Table 12.15 VectorBuilder: Vector Manufacturing Related Capabilities
Table 12.16 VectorBuilder: Recent Developments and Future Outlook
Table 12.17 AGC Biologics: Company Snapshot
Table 12.18 AGC Biologics: Vector Manufacturing Related Capabilities
Table 12.19 Aldevron: Company Snapshot
Table 12.20 Aldevron: Vector Manufacturing Related Capabilities
Table 12.21 Matica Biotechnology: Company Snapshot
Table 12.22 Matica Biotechnology: Vector Manufacturing Related Capabilities
Table 12.23 Resilience: Company Snapshot
Table 12.24 Resilience: Vector Manufacturing Related Capabilities
Table 13.1 Viral Vectors and Plasmid DNA Production in Europe: List of Profiled Companies
Table 13.2 Lonza: Company Snapshot
Table 13.3 Lonza: Vector Manufacturing Related Capabilities
Table 13.4 Lonza: Recent Developments and Future Outlook
Table 13.5 Touchlight: Company Snapshot
Table 13.6 Touchlight: Vector Manufacturing Related Capabilities
Table 13.7 Touchlight: Recent Developments and Future Outlook
Table 13.8 BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech): Company Snapshot
Table 13.8 BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech): Vector Manufacturing Related Capabilities
Table 13.9 Biovian: Company Snapshot
Table 13.10 Biovian: Vector Manufacturing Related Capabilities
Table 13.11 Celonic: Company Snapshot
Table 13.12 Celonic: Vector Manufacturing Related Capabilities
Table 13.13 Centre for Process Innovation: Company Snapshot
Table 13.14 Centre for Process Innovation: Vector Manufacturing Related Capabilities
Table 13.15 CEVEC Pharmaceuticals: Company Snapshot
Table 13.16 CEVEC Pharmaceuticals: Vector Manufacturing Related Capabilities
Table 13.17 NorthX Biologics: Company Snapshot
Table 13.18 NorthX Biologics: Vector Manufacturing Related Capabilities
Table 13.19 Novartis: Company Snapshot
Table 13.20 Novartis: Vector Manufacturing Related Capabilities
Table 13.21 Oxford BioMedica: Company Snapshot
Table 13.22 Oxford BioMedica: Vector Manufacturing Related Capabilities
Table 13.23 Sanofi: Company Snapshot
Table 13.24 Sanofi: Vector Manufacturing Related Capabilities
Table 14.1 Viral Vectors and Plasmid DNA Production in Asia-Pacific: List of
Profiled Companies
Table 14.2 CoJourney: Company Snapshot
Table 14.3 CoJourney: Vector Manufacturing Related Capabilities
Table 14.4 CoJourney: Recent Developments and Future Outlook
Table 14.5 Esco Aster: Company Snapshot
Table 14.6 Esco Aster: Vector Manufacturing Related Capabilities
Table 14.7 Esco Aster: Recent Developments and Future Outlook
Table 14.8 Wuxi AppTec: Company Snapshot
Table 14.9 Wuxi AppTec: Vector Manufacturing Related Capabilities
Table 14.10 Wuxi AppTec: Recent Developments and Future Outlook
Table 14.11 Altruist Biotechnology: Company Snapshot
Table 14.12 Altruist Biotechnology: Vector Manufacturing Related Capabilities
Table 14.13 Jiangsu Puxin Biopharmaceutical: Company Snapshot
Table 14.14 Jiangsu Puxin Biopharmaceutical: Vector Manufacturing Related Capabilities
Table 14.15 Nikon CeLL innovation: Company Snapshot
Table 14.16 Nikon CeLL innovation: Vector Manufacturing Related Capabilities
Table 16.1 Vector and Gene Therapy Manufacturing: List of Partnerships
Table 16.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships
Table 17.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions
Table 17.2 Vector and Gene Therapy Manufacturing: Information on Type of Manufacturing Facility
Table 17.3 Vector and Gene Therapy Manufacturing: Information on Scale of Operation, Type of Vector Manufactured and Application Area
Table 18.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 18.2 AAV Vector-based Therapy Developers: Likely Partners
Table 18.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 18.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 18.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 18.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 18.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 18.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 18.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 18.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 18.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 18.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 18.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 18.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 18.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 18.16 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 18.17 Other Viral Vector-based Therapy Developers: Likely Partners
Table 18.18 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 18.19 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 21.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions /Primary Research
Table 21.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 21.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 23.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 23.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 23.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 23.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 24.1. Global Annual Demand for Viral Vectors Manufacturing
Table 24.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), Till 2035
Table 24.3 Global Viral Vector Manufacturing Annual Supply (Scenario 2), Till 2035
Table 24.4 Global Viral Vector Manufacturing Annual Supply (Scenario 3), Till 2035
Table 24.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-based Cell and Gene Therapies)
Table 24.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 24.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), Till 2035
Table 24.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), Til 2035
Table 24.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 38.1 Survey Responses: Information on Participating Companies / Organizations
Table 38.2 Survey Responses: Information on Seniority Level of Respondents
Table 38.3 Survey Responses: Information on Type of Vector
Table 38.4 Survey Responses: Information on Scale of Operation
Table 38.5 Survey Responses: Information on Availability of Vector Stabilization Technology
Table 38.6 Survey Responses: Information on Type of Manufacturer (In-house Production versus Contract Services)
Table 40.1 HALIX: Key Highlights
Table 40.2 Batavia Biosciences: Key Highlights
Table 40.3 CEVEC Pharmaceuticals: Key Highlights
Table 40.4 Delphi Genetics: Key Highlights
Table 40.5 Clean Cells: Key Highlights
Table 40.6 Novasep: Key Highlights
Table 40.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 40.8 Massachusetts General Hospital: Key Highlights
Table 40.9 University of Nantes: Key Highlights
Table 40.10 CJ PARTNERS: Key Highlights
Table 40.11 ACGT: Key Highlights
Table 40.12 Polypus Transfection: Key Highlights
Table 40.13 Richter-Helm BioLogics: Key Highlights
Table 40.14 Plasmid Factory: Key Highlights
Table 40.15 Waisman Biomanufacturing: Key Highlights
Table 40.16 EFS-West Biotherapy: Key Highlights
Table 40.17 GEG Tech: Key Highlights
Table 40.18 ViveBiotech: Key Highlights
Table 40.19 Independent Consultant: Key Highlights
Table 41.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 41.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 41.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 41.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 41.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Table 41.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 41.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 41.10Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Table 41.11Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 41.12Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Table 41.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 41.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.15Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.16Plasmid DNA and Gene Therapy Manufacturers (Industry Players) Distribution by Location of Headquarters (Region)
Table 41.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 41.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 41.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 41.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 41.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Country)
Table 41.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 41.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 41.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters and Scale of Operation
Table 41.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Table 41.12 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation and Type of Viral Vector Manufactured
Table 41.13 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 41.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 41.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 41.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Region)
Table 41.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Country)
Table 41.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Table 41.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 41.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Region)
Table 41.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facility (Country)
Table 41.22 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 41.23 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 41.24 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 41.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Year of Establishment
Table 41.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Region)
Table 41.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters (Country)
Table 41.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer
Table 41.29 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Table 41.30 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 41.31 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation and Type of Vector Manufactured
Table 41.32 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 41.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 41.34 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 41.35 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Table 41.36 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector
Table 41.37 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 41.38 Most Active Players: Distribution by Number of Technologies
Table 41.39 Catalent Biologics: Annual Revenues
Table 41.40 Charles River Laboratories: Annual Revenues
Table 41.41 Thermo Fisher Scientific: Annual Revenues
Table 41.42 Lonza: Annual Revenues
Table 41.43 Wuxi AppTec: Annual Revenues
Table 41.44 Partnerships and Collaborations: Cumulative Year-wise Trend, Till 2025
Table 41.45 Partnerships and Collaborations: Distribution by Type of Partnership
Table 41.46 Partnerships and Collaborations: Distribution by Scale of Operation
Table 41.47 Partnerships and Collaborations: Distribution by Type of Vector Manufactured
Table 41.48 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 41.49 Partnerships and Collaborations: Distribution by Application Area
Table 41.50 Most Active Players: Distribution by Number of Partnerships
Table 41.51 Partnerships and Collaborations: Local and International Agreements
Table 41.52 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 41.53 Recent Expansions: Cumulative Year-wise Trend, Till 2025
Table 41.54 Recent Expansions: Distribution by Type of Expansion
Table 41.55 Recent Expansions: Distribution by Year and Type of Expansion
Table 41.56 Most Active Players: Distribution by Number of Expansions
Table 41.57 Most Active Players: Distribution by Amount Invested
Table 41.58 Recent Expansions: Distribution by Type of Manufacturing Facility
Table 41.59 Recent Expansions: Distribution by Scale of Operation
Table 41.60 Recent Expansions: Distribution by Type of Vector Manufactured
Table 41.61 Recent Expansions: Distribution by Application Area
Table 41.62 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 41.63 Recent Expansions: Distribution by Location of Expansion
Table 41.64 Viral Vector and Plasmid DNA Manufacturers: Distribution by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Table 41.65 Viral Vector and Plasmid DNA Manufacturers: Distribution by Type of Vector Manufactured and Company Size
Table 41.66 Viral Vector and Plasmid DNA Manufacturers Contract Manufacturing Organizations: Distribution by Geography
Table 41.67 Viral Vector and Plasmid DNA Manufacturers In-House Manufacturers: Distribution by Geography
Table 41.68 Viral Vector and Plasmid DNA Manufacturers In-House and Contract Manufacturing Organizations: Distribution by Geography
Table 41.69 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facility
Table 41.70 Adenoviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.71 Lentiviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.72 Retroviral Vector Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.73 Plasmid DNA Manufacturers: Distribution by Location of Headquarters and Scale of Operation
Table 41.74 Global Installed Viral Vectors Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Table 41.75 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size (Sample Data Set)
Table 41.76 Global Installed Viral Vector and Plasmid DNA Manufacturing
Capacity (in Liters): Distribution by Type of Vector Manufactured
Table 41.77 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Company Size
Table 41.78 Global Installed Viral Vector Manufacturing Capacity: Distribution by
Range of Installed Capacity (in Liters)
Table 41.79 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Table 41.80 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Table 41.81 Global Installed Viral Vector Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Table 41.82 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
Table 41.83 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 41.84 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Table 41.85 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Headquarters (Region)
Table 41.86 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Table 41.87 Global Demand for Viral Vector and Plasmid DNA (Thousand Patients), 2023-2035
Table 41.88 Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients), 2023-2035
Table 41.89 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Table 41.90 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Table 41.91 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Table 41.92 Global Clinical Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Table 41.93 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients), 2023-2035
Table 41.94 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Vector
Table 41.95 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Type of Therapy
Table 41.96 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Therapeutic Area
Table 41.97 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients): Distribution by Geography
Table 41.98 Global Vector Manufacturing Market, Historical Trends (Since 2025)
(USD Million)
Table 41.99 Global Vector Manufacturing Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.100 Vector Manufacturing Market for Preclinical Scale, Historical Trends (:
Since 2021) (USD Million)
Table 41.101 Vector Manufacturing Market for Preclinical Scale, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.102 Vector Manufacturing Market for Clinical Scale, Historical Trends (Since 2021) (USD Million)
Table 41.103 Vector Manufacturing Market for Clinical Scale, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.104 Vector Manufacturing Market for Commercial Scale, Historical Trends (Since 2021) (USD Million)
Table 41.105 Vector Manufacturing Market for Commercial Scale, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.106 Vector Manufacturing Market for AAV Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.107 Vector Manufacturing Market for AAV Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.108 Vector Manufacturing Market for Adenoviral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.109 Vector Manufacturing Market for Adenoviral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.110 Vector Manufacturing Market for Lentiviral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.111 Vector Manufacturing Market for Lentiviral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.112 Vector Manufacturing Market for Retroviral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.113 Vector Manufacturing Market for Retroviral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.114 Vector Manufacturing Market for Non Viral Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.115 Vector Manufacturing Market for Non Viral Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.116 Vector Manufacturing Market for Other Vectors, Historical Trends (Since 2021) (USD Million)
Table 41.117 Vector Manufacturing Market for Other Vectors, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.118 Vector Manufacturing Market for Cell Therapy, Historical Trends (Since 2021) (USD Million)
Table 41.119 Vector Manufacturing Market for Cell Therapy, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.120 Vector Manufacturing Market for Gene Therapy, Historical Trends (Since 2021) (USD Million)
Table 41.121 Vector Manufacturing Market for Gene Therapy, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.122 Vector Manufacturing Market for Vaccines, Historical Trends (Since
2021) (USD Million)
Table 41.123 Vector Manufacturing Market for Vaccines, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.124 Vector Manufacturing Market for Oncological Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.125 Vector Manufacturing Market for Oncological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.126 Vector Manufacturing Market for Rare Diseases, Historical Trends (Since 2021) (USD Million)
Table 41.127 Vector Manufacturing Market for Rare Diseases, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.128 Vector Manufacturing Market for Immunological Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.129 Vector Manufacturing Market for Immunological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.130 Vector Manufacturing Market for Neurological Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.131 Vector Manufacturing Market for Neurological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.132 Vector Manufacturing Market for Sensory Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.133 Vector Manufacturing Market for Sensory Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.134 Vector Manufacturing Market for Metabolic Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.135 Vector Manufacturing Market for Metabolic Disorders, Forecasted
Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.136 Vector Manufacturing Market for Blood Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.137 Vector Manufacturing Market for Blood Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.138 Vector Manufacturing Market for Musculoskeletal Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.139 Vector Manufacturing Market for Musculoskeletal Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.140 Vector Manufacturing Market for Infectious Diseases, Historical Trends (Since 2021) (USD Million)
Table 41.141 Vector Manufacturing Market for Infectious Diseases, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.142 Vector Manufacturing Market for Ophthalmic Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.143 Vector Manufacturing Market for Ophthalmic Disorders, Forecasted
Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.144 Vector Manufacturing Market for Autoimmune Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.145 Vector Manufacturing Market for Other Disorders, Historical Trends (Since 2021) (USD Million)
Table 41.146 Vector Manufacturing Market for Other Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.147 Vector Manufacturing Market for In-house Manufacturers, Historical Trends (Since 2021) (USD Million)
Table 41.148 Vector Manufacturing Market for In-house Manufacturers, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.149 Vector Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (Since 2021) (USD Million)
Table 41.150 Vector Manufacturing Market for Contract Manufacturing Organizations, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.151 Vector Manufacturing Market in North America, Historical Trend (Since 2021) (USD Million)
Table 41.152 Vector Manufacturing Market in North America, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.153 Vector Manufacturing Market in Europe, Historical Trend (Since 2021) (USD Million)
Table 41.154 Vector Manufacturing Market in Europe, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.155 Vector Manufacturing Market in Asia-Pacific, Historical Trend (Since 2021) (USD Million)
Table 41.156 Vector Manufacturing Market in Asia-Pacific, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.157 Vector Manufacturing Market in Middle East and North Africa, Historical Trend (Since 2021) (USD Million)
Table 41.158 Vector Manufacturing Market in Middle East and North Africa, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.159 Vector Manufacturing Market in Latin America and Rest of the World, Historical Trend (Since 2021) (USD Million)
Table 41.160 Vector Manufacturing Market in Latin America and Rest of the World, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 41.161 Survey Analysis: Distribution by Seniority Level of Respondents
Table 41.162 Survey Analysis: Distribution by Type of Manufacturer
Table 41.163 Survey Analysis: Distribution by Scale of Operation
Table 41.164 Survey Analysis: Distribution by Type of Vector Manufactured

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

4D Molecular Therapeutics
53Biologics
AavantiBios
Abbott
AbbVie
Abeona Therapeutics
Abintus Bio
Accinov (acquired by Advanced BioScience Laboratories)
Acucela
AcuraBio
Adaptimmune Therapeutics
AdaptVac
Addgene
Aduro Biotech
Advaccine
Advanced BioScience Laboratories
Advanced Biotherapeutics Consulting
Advantagene
Advaxis
Advent
Adverum Biotechnologies (formerly known as Avalanche Biotechnologies)
Aevitas Therapeutics (a subsidiary of Fortress Biotech)
AffyImmune Therapeutics
AffyXel
AGC Biologics
Agilent Technologies
Agilis Biotherapeutics (acquired by PTC Therapeutics)
Ajinomoto Bio-Pharma Services
Akdeniz University
Akron Biotech
Albumedix
Aldevron
Allele Biotechnology
Allergan
Allife Medicine
Allogene Therapeutics
Alma Bio Therapeutics
AlphaVax
ALSTEM
Althea Technologies
Altimmune
Altor BioScience
Altruist Biologics
American Gene Technologies
Amgen
Amicus Therapeutics
Ampersand Capital Partners
AMSBIO
Amsterdam BioTherapeutics Unit
Amsterdam Molecular Therapeutics (acquired by uniQure)
Anaeropharma Science
Andelyn Biosciences
Anemocyte
AnGes
Angionetics
ANLBIO
Annapurna Therapeutics (acquired by Avalanche Biotechnologies)
apceth Biopharma (subsidiary of Hitachi Chemical)
Applied Biological Materials
Applied Genetic Technologies (AGTC)
Applied StemCell
Applied Viromics
Arcellx
ArcticZymes Technologies
Areta International
Arranta Bio (acquired by Recipharm)
Aruvant Sciences
ASC Therapeutics
AskBio
Asklepios BioPharmaceutical
Astellas Pharma
AstraZeneca
Atara Biotherapeutics
Atlantic Bio GMP (a subsidiary of Atlanpole Biotherapies)
Atsena Therapeutics
Audentes Therapeutics (acquired by Astella Pharma)
Augusta University
Aurigene Pharmaceutical Services
Aurora Biopharma
Autolus Therapeutics
Avantor
Avecia Biologics
Avid Bioservices
AVROBIO
Axovant Gene Therapies
Bamboo Therapeutics
Batavia Biosciences
Baylor College of Medicine
BCM Families Foundation
Beacon Biotherapeutics
Beam Therapeutics
Beckman Research Institute
Beijing Biohealthcare Biotechnology
Beijing Doing Biomedical
Beijing Hetang Shenghua Medical Technology
Beijing HuiNengAn Biotech
Beijing Immunochina Medical Science & Technology
Beijing Mario Biotech
Beijing Sanwater Biological Technology
Bellicum Pharmaceuticals
Benitec Biopharma
BIA Separations (acquired by Sartorius)
Bioceltech Therapeutics
BioCentriq (acquired by GC)
BioCina
Biogen
Bio-Gene Technology
BioInvent International
Biological E.
BioMarin Pharmaceuticals
Biomay
Biomiga
Bionic Sight
BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
Bio-Rad Laboratories
BioReliance (a subsidiary of Merck KGaA)
Bio-Synthesis
BioVec Pharma
Bioverativ
Biovian
BioVision
Blue Sky BioServices (a subsidiary of LakePharma)
bluebird bio (formerly known as Genetix Pharmaceuticals)
BMS
Boehringer Ingelheim BioXcellence
BoYuan RunSheng Pharma
Brain Neurotherapy Bio
Brammer Bio (acquired by Thermo Fisher Scientific)
Brazilian Biosciences National Laboratory (LNBio)
Bristol Myers Squibb
Cabaletta Bio
Caltech
Cambridge Gene Therapy
Candel Therapeutics
Capsugel
Carina Biotech
Carmine Therapeutics
CARsgen Therapeutics
Cartesian Therapeutics
Casey Eye Institute
Castle Creek Biosciences
Catalent Biologics
Celgene
Cell and Gene Therapy Catapult
Cell Biolabs
Cellectis
CellGenTech
Cellular Biomedicine Group
CellVec
Celonic
Celsion
Celyad Oncology
Center for Breakthrough Medicines
Centre for Commercialization of Regenerative Medicine
Centre for Process Innovation
Cepham Life Sciences
CEVEC Pharmaceuticals
CG Oncology
Charles River Laboratories
Children’s Medical Research Institute (CMRI)
Children's Hospital of Philadelphia
China Immunotech Biotechnology
Choroideremia Research Foundation
Cincinnati Children's Hospital Medical Center
City of Hope
Clean Cells
CLINO
Cognate BioServices
CoJourney
CombiGene
Copernicus Therapeutics
Cornell University
Creative Biogene
Creative Biolabs
CSL Behring
Curia
Cytiva (formerly known as GE Healthcare Life Sciences)
CytoMed Therapeutics
Cytovance Biologics
Daiichi Sankyo
Decibel
Delphi Genetics
Denali Therapeutics
Department of Cell and Chemical Biology, Leiden University Medical Center
DiNAMIQS
DiNAQOR
DNAtrix
Duke University
Durham
Dyno Therapeutics
Editas Medicine
ElevateBio
Elixirgen Scientific
Emendo Biotherapeutics
Emergent BioSolutions
Emory University School of Medicine
enGene
Epeius Biotechnologies
Errant Gene Therapeutics
Erytech Pharma
Esco Aster
Esteve
eTheRNA immunotherapies
EUFETS
Eureka Biotechnology
Eurofins Genomics
Eurofins Scientific
ExcellGene
Exothera
Expression Therapeutics
Eyevensys
Fate Therapeutics
FerGene
FIMA
FinVector (formerly known as Ark Therapeutics)
Five Prime Therapeutics
Flash Therapeutics
Flexion Therapeutics
Florida Biologix
Forecyte Bio
Forge Biologics
Formula Pharmaceuticals
Fortress Biotech
Fosun Pharma
Foundation Fighting Blindness
Fraunhofer Institute for Toxicology and Experimental Medicine
Freeline Therapeutics
FUJIFILM Diosynth Biotechnologies
Fundamenta Therapeutics
G-CON Manufacturing
GE Healthcare Life Sciences
GEG Tech
Genable Technologies
GeneCopoeia
GeneCure Biotechnologies
GeneDetect
GeneImmune Biotechnology
Genelux
GeneMedicine
Genenta Science
GeneOne Life Science
Genethon
GENEWIZ
Genexine
Genezen Laboratories
GenIbet Biopharmaceuticals
Genopis (acquired by Wacker Biotech)
Genovac
Genprex
GenScript
GenSight Biologics
GenVec
Gen-X
Genzyme
GeoVax Labs
GIGA
GlaxoSmithKline
Gracell Biotechnologies
Gradalis
Green Cross LabCell
Grousbeck Gene Therapy Center
Guangdong Xiangxue Precision Medical Technology
Guangdong Zhaotai InVivo Biomedicine
Guangzhou Anjie Biomedical Technology
Guangzhou FineImmune Biotechnology
Gyroscope Therapeutics
Hadassah Medical Organization
HaemaLogiX
HALIX
Handl Therapeutics
Hanmi Bio Plant (a subsidiary of Hanmi Pharm)
Harvard Gene Therapy Initiative
Hebei Senlang Biotechnology
Heidelberg University Hospital
Helixmith
Hemera Biosciences
Henan Hualong Biotechnology
Herantis Pharma
Hitachi Chemical Advanced Therapeutics Solutions
Holostem Terapie Avanzate
Homology Medicines
Hong Kong Institute of Biotechnology
Hookipa Biotech
HORAMA
Hrain Biotechnology
Huadao biomedical
Huapont Life Sciences
Human Stem Cells Institute
Hunan Zhaotai Yongren Medical Innovation
Icahn School of Medicine at Mount Sinai
iCAR Bio Therapeutics
iCarTAB BioMed
iCell Gene Therapeutics
ID Pharma (formerly known as DNAVEC)
IDT Biologika
Ilya Pharma
Immatics
Immune Design
Immune Technology
Immunocore
Immunomic Therapeutics
Imperial Innovations
Imperial Innovations
Indiana University
Innovative Cellular Therapeutics
InnovaVector
INOVIO Pharmaceuticals
InProTher
Institute for Bioengineering of Catalonia
Institute of Medical Science Research Hospital
Institute of Translational Health Sciences
International AIDS Vaccine Initiative (IAVI)
InvivoGen
IPPOX Foundation
IQVIA (formerly known as QuintilesIMS)
Iveric Bio
JAFRAL Biosolutions
Jansen Pharmaceuticals
Jiangsu Puxin Biomedicine
Juno Therapeutics
Juventas Cell Therapy
JW Therapeutics
KAEDI
Kaneka Eurogentec
Karolinska Institute
Karolinska University Hospital
Kavli Institute for Systems Neuroscience
Kecellitics Biotech
King's College London
Kite Pharma (a subsidiary of Gilead Sciences)
KMD Bioscience
Kobe Biomedical Innovation Cluster
Kolon TissueGene
Kriya Therapeutics
Krystal Biotech
Kuur Therapeutics
Laboratory of Digital Sciences of Nantes
LakePharma (acquired by Curia)
Legend Biotech
Leiden University Medical Centre
Lentigen Technology
Leucid Bio
Leukocare
Leuven Viral Vector Core (LVVC)
Lexeo
LEXEO Therapeutics
Lion TCR
Lipigon Pharmaceuticals
LNBio
LogicBio Therapeutics
LOKA Biosciences
Lokon Pharma
Lonza
Louisiana State University School of Veterinary Medicine
Luina Bio
Luminous BioSciences
Lund University
Lysogene
Magee-Womens Research Institute
Maine Medical Center Research Institute (MMCRI)
MaineHealth Institute for Research
MaineHealth Institute for Research (MHIR)
MangoGen Pharma
Marino Biotechnology
Mass Biologics
Massachusetts Eye and Ear
Massachusetts General Hospital
MassBiologics
Matica Biotechnology
MaxCyte
Mayflower Bioscience
Mayo Clinic Cancer Center
McMaster Immunology Research Centre (MIRC)
MD Anderson Cancer Institute
medac
Medigene
MedImmune
MeiraGTx
Memorial Sloan Kettering Cancer Center
Merck
MicroBiopharm Japan
Microsoft
Mila’s Miracle Foundation
MilliporeSigma
Milo Biotechnology
Miltenyi Biotec
Minerva Biotechnologies
MingJu Therapeutics
Mitsubishi Tanabe Pharma
Moderna
Molecular Diagnostic Services
MolMed (acquired by AGC Biologics)
Momotaro-Gene
MultiVir
Mustang Bio
Mycenax Biotech
Myeloma Crowd
Nanjing Bioheng Biotech
Nantes Gene Therapy Institute
Naobios (a subsidiary of Clean Biologics)
National Cancer Institute
National Center for Advancing Translational Sciences
National Human Genome Research Institute
National Institute of Allergy and Infectious Diseases
National Institute of Environmental Health Sciences
National Institute of Neurodegenerative Disorders and Stroke
Nationwide Children's Hospital
Naval Medical Research Center
Neurimmune
NeuroCure
Neurophth Therapeutics
Neuroscience Center Zurich
New Jersey Innovation Institute (NJII)
NewLink Genetics
NHS Blood and Transplant
Nikon CeLL innovation
Noga therapeutics
Norgen Biotek
Northern RNA
NorthX Biologics
Nouscom
Novartis
Novartis Gene Therapies
Novasep
Novavax
OBiO Technology
Odylia Therapeutics
OHSU Casey Eye Institute
Okairos
Omnia Biologics
OmniaBio
Oncolys BioPharma
OncoSenX
ORCA Therapeutics
Oregon Health & Science University
Orgenesis
Otonomy
Oxford BioMedica
Oxford Genetics
OXGENE
OZ Biosciences
PackGene Biotech
PACT Pharma
Pall Biotech
Paragon Bioservices
Paras Biopharmaceuticals
Passage Bio
PeriphaGen
PerkinElmer
PersonGen BioTherapeutics
Peter MacCallum Cancer Centre
Pfizer
PharmaCell
pHion Therapeutics
PhorMed
Pinze Lifetechnology
PlasmidFactory
Porton Advanced Solutions
Poseida Therapeutics
Precigen
Precision BioSciences
Pregene Biotechnology
Prevail Therapeutics
Prime Vector Technologies
ProBioGen
PROGEN
Progenics Pharmaceuticals
ProMab Biotechnologies
Protheragen
Provecs Medical
PsiOxus Therapeutics
PTC Therapeutics
Puresyn
Quethera (acquired by Astellas Pharma)
Regeneron Pharmaceuticals
REGENXBIO
ReiThera
Renova Therapeutics
Rentschler Biopharma
Resilience
Richter-Helm BioLogics
Roche
Rocket Pharmaceuticals
Roswell Park Comprehensive Cancer Center
Rznomics
SAB Technology
SAFC
Saiba Biotech
Salk
Sanford Burnham Prebys
Sangamo Therapeutics
Sanofi
Santen Pharmaceutical
Sarepta Therapeutics
Sartorius Stedim Biotech
Scancell
Scorpius BioManufacturing
Seattle Children's Research Institute (SCRI)
Selecta Biosciences
Sensorion
Senti Biosciences
Servier
Shanghai Biomed-Union Biotechnology
Shanghai Bioray Laboratory
Shanghai Cell Therapy Group
Shanghai GeneChem
Shanghai Longyao Biotechnology
Shanghai PerHum Therapeutics
Shanghai Sunway Biotech
Shanghai Unicar-Therapy Bio-medicine Technology
Shenzhen Binde Biotechnology
Shenzhen Sibiono GeneTech
SignaGen Laboratories
SillaJen
Simcere Pharmaceutical
Sinobioway Cell Therapy
SIRION Biotech
Skyline Therapeutics
Solid Biosciences
Sorrento Therapeutics
Southern RNA
Spark Therapeutics
SQZ Biotechnologies
St. Jude Children's Research Hospital
Stanford University
Symbiosis Pharmaceutical Services
Synpromics
Synthace
System Biosciences
Takara Bio
Takeda Pharmaceutical
Tamid Bio (a subsidiary of Fortress Biotech)
Targovax
Taysha Gene Therapies
TCR2 Therapeutics
TCRCure Biopharma
tebu-bio
Telethon Institute of Genetics and Medicine (TIGEM)
Terry Fox Laboratory
Tessa Therapeutics
The Beijing Pregene Science and Technology
The Hong Kong Institute of Biotechnology
The Hormel Institute
The Jackson Laboratory
The Jenner Institute
The Michael J. Fox Foundation
The Native Antigen Company
The University of Queensland
The University of Tennessee Health Science Center
The Vector Core, University of North Carolina
Themis (acquired by Merck)
TheraBiologics
TheraVectys
Thermo Fisher Scientific
Tianjin Mycure Medical Technology
Timmune Biotech
Tmunity Therapeutics
Tolerion
Touchlight
Transgene
Treadwell Therapeutics
Treeway
TriLink BioTechnologies (a subsidiary of Maravai LifeSciences)
Trizell
Twist Bioscience
TxCell
uBriGene Biosciences
UC Davis
UC San Diego School of Medicine
UK Cystic Fibrosis Gene Therapy Consortium
Ultragenyx Pharmaceutical
uniQure
Univercells
University Hospital Tuebingen
University Medical Center Groningen
University of Adelaide
University of California
University of Eastern Finland
University of Florida
University of Iowa
University of Maryland
University of Michigan Health
University of Minnesota
University of North Carolina
University of Pennsylvania
University of Pittsburgh
University of South Carolina School of Medicine
University of Southampton
University of Tennessee Health Science Center
University of Tokyo
University of Virginia School of Medicine
Urovant Sciences
USC School of Pharmacy
UT Southwestern Medical Center
Vaccine Manufacturing and Innovation Centre (VMIC)
Vaccitech
VBL Therapeutics
VCN Biosciences
Vectalys
Vector Biolabs
Vector BioMed
VectorBuilder
Vecura
Versiti Blood Research Institute
VGXI
Vibalogics (acquired by Recipharm)
Vigene Biosciences (acquired by Charles River Laboratories)
Vineti
Viralgen (a subsidiary of Asklepios BioPharmaceutical)
Virapur
ViraQuest
ViroCell Biologics
ViroMed
Virovek
VIVEbiotech
Voyager Therapeutics
VVector Bio
VWR (a subsidiary of Avantor)
Wacker Biotech
Waisman Biomanufacturing
Washington University School of Medicine
Wellington Zhaotai Therapies
WhiteLab Genomics
Wuhan Bio-Raid Biotechnology
Wuhan Sian Medical Technology
WuXi AppTec
Wyvern Pharmaceuticals
Xiangxue Life Sciences
Xpress Biologics
XyloCor Therapeutics
Xyphos Biosciences
Yake Biotechnology
Yonsei University Health System
Yposkesi
Yufan Biotechnologies
Ziopharm Oncology

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4331EUR$4,799USD£3,763GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6316EUR$6,999USD£5,488GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16243EUR$17,999USD£14,112GBP